New open access journal highlights methods and clinical trial results

The first issue of Elsevier's new open access journal Contemporary Clinical Trials Communications features a new method to make cancer clinical trials more effective, a better way of determining whether a trial was successful and a dashboard that helps patients enroll in trials. The journal is a spin-off of the well-established title Contemporary Clinical Trials.

There are many ways to carry out a clinical trial. Researchers need to think about the number of patients to enroll, the type of treatments to give and their frequency, among many other factors. Contemporary Clinical Trials Communications publishes methodology and statistics that answer these questions, helping researchers build on each other's work and design better trials.

For example, in the first issue of the journal, which is now available on ScienceDirect, researchers from Genentech Inc. and the Deerfield Institute describe a new trial design that helps researchers take into account delayed effects of immune-oncology treatments.

"I trust that the readers will find the journal a valuable source of recent advancements in clinical trials," said Dr. Zhezhen Jin, co-Editor-in-Chief of Contemporary Clinical Trials Communications and Professor of Biostatistics at Columbia University in New York. He also explained that this knowledge can "facilitate the design, conduct and analysis of their trials."

The journal also aims to tackle the problem of publication bias towards positive results by making all trial data open access.

"A major objective of the journal is to reduce publication bias, which is a major issue in the field of clinical trials," said Dr. Zheng Su, co-Editor-in-Chief of Contemporary Clinical Trials Communications and VP at the Deerfield Institute in New York.

There are two main approaches to clinical trials: randomized and non-randomized. In randomized trials, the participants do not know whether they are receiving the treatment or a placebo. In non-randomized trials, the participants are often all given the treatment. Many clinical trials journals only publish randomized trials, but Contemporary Clinical Trials Communications will publish both.

"There are several existing clinical trials journals that either give preferential treatment to positive trial results due to their perceived higher significance, or focus only on randomized trials," added Dr. Jin. "In contrast, Contemporary Clinical Trials Communications provides a platform for trialists around the world to share their knowledge on all aspects of clinical trials. We're making scientifically valid and technically sound original research findings freely accessible regardless of their perceived importance or impact."

Contemporary Clinical Trials Communications is now open for submissions. The first issue is published on ScienceDirect.

About Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications is an international, peer-reviewed, open access journal that publishes articles on all aspects of clinical trials, including design, conduct, analysis, regulation and ethics. Articles appeal to a wide range of disciplines. Contemporary Clinical Trials Communications strives to increase the transparency of medical research and reduce publication bias by publishing scientifically valid original research findings, irrespective of their perceived importance, significance or impact.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc, a world-leading provider of information solutions for professional customers across industries.

Most Popular Now

Top 20 World Pharma News of 2016

Look back at the most prominent moments from the year 2016. We are proud to announce the 20 most popular World Pharma News from 2016, the most commonly viewed news accord...

Read more

Sanofi and Boehringer Ingelheim confirm Closing of…

Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) an...

Read more

Diabetes, heart disease, and back pain dominate US…

Just 20 conditions make up more than half of all spending on health care in the United States, according to a new comprehensive financial analysis that examines spending ...

Read more

FDA approves first drug for spinal muscular atroph…

The U.S. Food and Drug Administration has approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare ...

Read more

Novartis invests in next generation therapies to r…

Novartis announced today a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments...

Read more

Topical treatment activates immune system to clear…

A combination of two FDA-approved drugs - a topical chemotherapy and an immune-system-activating compound - was able to rapidly clear actinic keratosis lesions from patie...

Read more

Vaccine shows promising results for early-stage br…

Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer ...

Read more

Bristol-Myers Squibb announces immunotherapy clini…

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squi...

Read more

Anti-aging therapies targeting senescent cells: Fa…

It's an exciting time to be an elderly mouse. Researchers believe that by removing senescent cells (cells with a persistent damage response), which naturally accumulate w...

Read more

Novo Nordisk and Glooko partner to develop digital…

Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabet...

Read more

FDA grants Roche's cancer immunotherapy TECENTRIQ …

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA)...

Read more

AstraZeneca and Lilly to develop second potentiall…

AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]